|Pendopharm offers a strong orthopedics portfolio for the treatment of OA of the knee.||
One injection for fast pain relief
One injection for long-term pain relief
Three injections for long-term pain relief
|Fast pain relief|
|Clinically proven long-term pain relief|
|Generally well tolerated|
|Light cross-linking properties of HA for better8
|Injection volume||4 mL||4 mL||2 mL|
|An effective HA concentration||22 mg/mL||20 mg/mL||15 mg/mL|
|Total HA delivered/injection||88 mg||80 mg||30 mg|
|More information||More information||More information|
Cingal™ (hyaluronic acid and triamcinolone hexacetonide) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics (e.g., acetaminophen). Cingal includes an ancillary steroid to provide additional short-term pain relief.1
Monovisc® is indicated in the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics, e.g. acetaminophen.1
Orthovisc® is indicated for the symptomatic treatment of osteoarthritis (OA) of the knee.
Copyright © 2016 Pharmascience Inc. Montreal, H4P 2T4 Canada. All rights reserved.
CingalTM, Monovisc® and Orthovisc® may not be suitable for everyone. Talk to your doctor if you have questions regarding these products, or for more information on pain associated with osteoarthritis of the knee. Product information is only pertinent for use in Canada. CingalTM, Monovisc® and Orthovisc® are trademarks of Anika Therapeutics Inc., used under licence by Pharmascience Inc. Pendopharm, Division of Pharmascience Inc. Product Licences are pertinent to use in Canada. Product Licences herein are not approved for use in the U.S.